Atlas Trials

Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2-negative Advanced Breast Cancer: a Prospective, Randomized, Open-label Phase Ⅱ Clinical Trial

Clinical trial NCT06176534 · RECRUITING

Trial details

NCT number
NCT06176534
Sponsor
Henan Cancer Hospital
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Advanced Breast CancerTreatmentHR Low/HER2 Negative
Start date
2024-01-01
Primary completion
2025-12-20
Enrollment
240

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.